Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
Rhea-AI Summary
Axsome Therapeutics (NASDAQ:AXSM) announced a settlement resolving all patent litigation related to SUNOSI (solriamfetol) in the United States. The cases stemmed from generic companies’ ANDA filings.
According to Axsome, five companies may sell generic SUNOSI starting on or after Sept 1, 2040 with pediatric exclusivity, or Mar 1, 2040 without, subject to FDA approval and customary conditions. No other SUNOSI patent litigation is pending, and the settlement will be submitted to the FTC and DOJ for review.
Positive
- All U.S. SUNOSI (solriamfetol) patent litigation has been fully resolved
- Generic SUNOSI entry deferred until 2040, depending on pediatric exclusivity status
- Only five companies granted rights to sell generic SUNOSI under the settlement
- No other SUNOSI-related patent cases remain pending, reducing legal uncertainty
Negative
- Settlement grants five companies rights to sell generic SUNOSI from 2040, introducing future competition
News Market Reaction – AXSM
In the Jun 3 session, AXSM gained 5.10%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.7% during that session. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Awareness partnership | Positive | -1.8% | Support for migraine awareness campaigns and patient education resources. |
| May 27 | Investor conferences | Positive | +0.1% | Announcement of participation in multiple June 2026 investor conferences. |
| May 26 | Clinical data updates | Positive | -0.8% | New AUVELITY and solriamfetol data presented at ASCP 2026. |
| May 07 | Awareness campaign | Positive | -1.1% | Recognition of Mental Health Month with resources and awareness efforts. |
| May 05 | Investor conferences | Positive | -0.3% | Planned fireside chats at major May 2026 healthcare conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including awareness campaigns and scientific updates, has often been followed by modestly negative next-day price moves despite generally positive or supportive content.
Over the past month, Axsome has focused on awareness, investor outreach, and clinical data visibility. On May 5 and May 27, it announced participation in multiple investor conferences, with small next-day moves of -0.29% and +0.14%. Awareness efforts for Mental Health Month (May 7) and Migraine & Headache Month (June 1) alongside AUVELITY and solriamfetol data presentations at ASCP 2026 (May 26) all saw mildly negative reactions. Today’s SUNOSI patent settlement fits into an active news flow around CNS brands.
Key Terms
abbreviated new drug applications regulatory
u.s. food and drug administration regulatory
pediatric exclusivity regulatory
generic version regulatory
settlement agreement regulatory
u.s. federal trade commission regulatory
u.s. department of justice regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsome’s product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications to the U.S. Food and Drug Administration by companies seeking approval to market a generic version of SUNOSI in the United States.
Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement agreement with the only remaining first-to-file generic applicant with pending patent litigation related to Axsome’s product SUNOSI. As part of the resolution of these lawsuits, Axsome will grant five companies the right to sell generic versions of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type. No other patent litigation relating to SUNOSI remains pending.
As required by law, Axsome will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
